Project Grant R01HL184386
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $890K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Trustees of The University of Pennsylvania $248,266 on January 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of sex chromosomes in neonatal hyperoxic lung injury as a mechanism of bronchopulmonary dysplasia. The recipient will interrogate dosage sensitivity of sex chromosomes and the X-linked gene KDM6A in an early-life hyperoxia mouse model of bronchopulmonary dysplasia. The research...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- The National Heart, Lung, and Blood Institute awarded Pennsylvania State University (Penn State Milton S. Hershey Medical Center) $178,092 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of surfactant protein A and receptor SP-R210 signaling in bronchopulmonary dysplasia. The research addresses the pathogenesis of bronchopulmonary dysplasia (BPD), a significant respiratory cause affecting more than 15,000 premature infants...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $384,428 on February 1, 2026, to investigate the role of dietary fatty acids in shaping lung macrophage homeostasis and inflammatory function under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds basic research examining how saturated fat enrichment alters innate immune cell activation in the lung, with focus on obesity-associated asthma pathophysiology. The research involves...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $177,355 on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the X chromosome in chronic obstructive pulmonary disease through integrated multi-omic approaches. The research integrates X chromosome whole genome sequencing, DNA methylation, and gene expression data from lung and blood samples across four cohorts—COPDGene, LTRC, LTCOPD, and Eclipse—to...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $360,418 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrated host-microbe classifiers for diagnosing lower respiratory tract infection in children using metagenomic next-generation sequencing applied to non-invasive samples including nasopharyngeal swabs and whole blood. The project addresses diagnostic gaps in pediatric...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $1,818,088 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how postnatal hypoxemia—reduced blood oxygen levels present in cyanotic congenital heart disease—impacts cardiac maturation and surgical recovery outcomes in pediatric patients. The project will examine the interaction between hypoxemia, myocardial immaturity, and postoperative complications through...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $1,231,094 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to decipher the molecular mechanism of pediatric interstitial lung disease caused by surfactant protein C (SFTPC) gene mutations and advance targeted therapies. The University of Pennsylvania research team, led by Dr. Jeremy Katzen, will develop and leverage in vivo mouse models and human induced...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $128,466 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a patient-oriented research program led by Dr. Elizabeth Foglia, an Associate Professor of Pediatrics in the Division of Neonatology, focused on improving neonatal respiratory outcomes by optimizing non-invasive ventilation and improving neonatal airway management. The award funds a K24 mentoring...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $268,500 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct multi-omic and network analysis investigating the role of X-linked transcription factors in chronic obstructive pulmonary disease heterogeneity. The research applies gene regulatory network analysis to multi-omic datasets from blood and lung tissue across four large COPD cohort studies (COPDGene, LTRC,...